Key result
Congenital Chagas screening in at-risk pregnancies costs ~€15,192 per QALY gained vs no screening.
Why the study?
Chagas disease is an emerging concern in Europe, where congenital transmission is the main route of new infections, but the cost-effectiveness of screening at-risk pregnant women and newborns in Italy was unestablished.
Does a congenital Chagas disease screening program improve cost-effectiveness compared to no screening in pregnant women at risk of infection in Italy?
Does a congenital Chagas disease screening program improve cost-effectiveness compared to no screening in pregnant women at risk of infection in Italy?
Screening for congenital Chagas disease in at-risk pregnant women in Italy is highly cost-effective, supporting its integration into maternal care pathways.
Answers are grounded in this paper and cite their sources.
May support Chagas screening evaluation in Italy; leaves open broader adoption pending real-world confirmation.
Chagas disease (CD) is an emerging public health concern in Europe. In non-endemic countries, congenital transmission is the main route of new infections. Italy is the second-largest host country in Europe for Latin American migrants and the prevalence of the disease is estimated around 3.5%. The aim is to evaluate the cost-effectiveness of a congenital CD screening program in pregnant women at risk of infection living in Italy and their newborns. We conducted a cost-effectiveness analysis from the perspective of the Italian National Health Service, comparing a screening scenario with a no-screening scenario. A Bayesian decision tree model with a lifetime horizon was developed. In the base-case analysis, the screening strategy yielded an incremental cost-effectiveness ratio of €15,193 per quality-adjusted life year gained (95% CI: €14,885–€15,552), falling well within the accepted cost-effectiveness threshold (€30,000–€50,000) in Italy. Probabilistic sensitivity analysis confirmed the robustness of these findings. Here we show that screening for congenital CD is a cost-effective strategy that improves health outcomes and aligns with international public health priorities. Our findings support the implementation of a national screening program integrated within existing maternal care pathways, contributing to the prevention of neglected tropical diseases and the promotion of migrant health. In non-endemic settings, congenital transmission is the primary infection route for Chagas disease. Here, the authors demonstrate that, in the Italian setting, targeted screening of at-risk pregnant women is a cost-effective strategy for prevention of disease in women and newborns.
No takes yet. Share an insight, caveat, or question.
Marraffa et al. (2025) studied Congenital Chagas disease (n=1,000). Congenital Chagas disease screening program vs. No screening was evaluated on Incremental cost-effectiveness ratio (ICER) per QALY gained (ICER €15,192 per QALY gained, 95% CI 14,885-15,552). A congenital Chagas disease screening program for at-risk pregnant women and their newborns yielded an incremental cost-effectiveness ratio of €15,192 per QALY gained compared to no screening.
Synapse has enriched 10 related papers. Consider them for comparative context: